​

1. Oncolipin-IT Melanoma (Multilamellar coalescent vesicle, MLCV):

• Description: Synthetic multilamellar liposomes with recombinant human IL-2, produced on Oncolipin platform technology

• Stage: Pre-clinical animal model research

• Clinical indication: For “in-situ” vaccination (Neville et al, Cytokine, 2001, 16: 239) of patients with melanoma.

• PI: To be determined (TBD)

​

2. Oncoquest™-PC:

• Description: Aggregon® with a recombinant human IL-2 and off-the-shelf common tumor antigen(s) found in Prostate cancer 

• Stage: Research phase

• Clinical indication: Patients with early stage prostate cancer;

• PI: To be determined (TBD)